ArticleBioinformation2026
Transcriptomic profiling for identifying differentially expressed genes in aneurysm.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneurysm progression is associated with complex molecular alterations that are insufficiently studied at transcriptomics level. An aneurysm is characterized as a bulge or a weak spot in a blood artery's wall that causes the vessel to abnormally enlarge or balloon, exceeding 50% of its normal diameter. In the present study aneurysm RNA sequencing (RNA-Seq) dataset involving 14 samples, which include 7 controls and 7 treatments was selected for the analysis. Pathway analysis showed the involvement of key genes in major shifts within lipid metabolism pathways. The protein-protein interaction (PPI) network analysis using the STRING database identified key hub genes that were significantly differentially expressed, including LIPE, SREBF1, SCARB2, LPL, PNPLA2, UCP1, CIDEC, DGAT2, CIDEA and FABP4. These key gene-encoded proteins may be prominent drug targets for future interventions aimed at treating aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.